What antibodies are typically associated with Limited cutaneous systemic sclerosis (CREST syndrome)?

Limited cutaneous systemic sclerosis, often referred to as CREST syndrome, is characterized by specific serological markers that can help in its diagnosis. The hallmark of CREST syndrome is the presence of anti-centromer antibodies (ACAs). These antibodies are particularly associated with limited forms of scleroderma and can be detected in a significant number of patients who present with this condition.

In contrast to limited scleroderma, diffuse systemic sclerosis is typically associated with the presence of anti-SCL-70 antibodies (also known as anti-topoisomerase-1 antibodies). While both limited and diffuse forms may present with positive antinuclear antibodies (ANA), and while rheumatoid factor (RF) may also appear in various autoimmune conditions, these are not specific to CREST syndrome.

Therefore, the correct answer aligns with understanding the specific autoantibodies associated with limited cutaneous systemic sclerosis, thereby highlighting the relevance of anti-centromer antibodies. This distinction is vital for accurate diagnosis and management of patients with scleroderma.